Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
June 19, 2025 01:00 ET Â | Source: Addex Therapeutics Strong cash position…
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
June 18, 2025 01:00 ET Â | Source: Addex Therapeutics Geneva, Switzerland, June…
Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting…
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
June 13, 2025 09:00 ET Â | Source: RAPT Therapeutics, Inc. SOUTH SAN…
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the…
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
Vancouver, Canada, June 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Engages Leading…
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
1-for-60 reverse stock split to become effective as of the opening of…
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development
NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a…
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
June 06, 2025 16:01 ET Â | Source: Keros Therapeutics, Inc. LEXINGTON, Mass.,…
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease…